GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022

Adding Multi-Cancer Early Detection (MCED) Screening to Standard of Care Screening More Than Doubled the Number of Cancers Detected 71% of Participants With MCED-Detected Cancers Had Cancer Types With No Routine Screening Tests Available Approximately Half of the MCED-Detected New Cancers Were Stage I or II MCED-Predicted Cancer Signal Origin Had 97.1% Accuracy and Enabled … Continue reading GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022